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Summary 
Three recent studies, approaching the question from different angles and using different and/or 
overlapping models, provide compelling evidence for the involvement of tumor-infiltrating B cells in 
the initiation and progression of pancreatic ductal adenocarcinoma (PDAC). These studies highlight 
the need for a better understanding of tumor-immune system interactions and the immunological 
mechanisms that promote or inhibit tumorigenesis, paving the way for better treatment strategies.  
 
Main text 
Treatment of pancreatic cancer has proven very difficult because of both the non-immunogenic nature 
of the tumor and the late stages at diagnosis. This is reflected in the abysmal 5-year survival rate of ~7% 
and the harsh standard-of-care (SOC) for patients. The most common treatment, aside from palliative 
care or surgery in eligible patients, is gemcitabine, which is a general DNA damaging agent. However, 
those patients healthy enough to handle strong treatment side effects are given a cocktail of four drugs 
called FOLFIRINOX in the hope of stalling tumor development (FDA.gov). Other FDA-approved 
drug combinations may be tried as the first-line treatment, but all have appalling side effects 
impacting patient quality of life without much measurable benefit. Although no immunotherapies are 
currently approved for treating pancreatic cancers, there are 16 clinical trials of various 
immunotherapies for pancreatic cancer (clinicaltrials.gov). These trials fall into two categories: 
combination therapies and vaccines. Most of the combination therapies involve adding an 
immunotherapy like checkpoint blockade, vaccine, or cytokines to the SOC, aiming to first make 
PDAC immunogenic, and then promote anti-tumor immune responses (1). 
 
Studies in both human and animal models have now demonstrated that the immune system plays a 
critical role in modulating the outcome of tumor development. In general, cytotoxic CD8 T cells, Th1-
type CD4 T cells, and natural killer (NK) cells exhibit anti-tumor activity while myeloid-derived 
suppressor cells (MDSCs) and tumor-associated macrophages (TAM) suppress anti-tumor immune 
responses and promote tumor progression and metastasis (2). Increasingly, B cells are also found to 
play a significant role in modulating the growth and progression of solid tumors (2, 3). Tumor-
infiltrating lymphocytic B cells (TIL-B) are a major component of TILs in breast cancer and advanced 
ovarian cancer, and their presence correlates with improved survival. However, in multiple mouse 
models, tumor development is enhanced when B cells are present. Growth of EL-4 thymoma, MC38 
colon cancer, and EMT-6 breast cancer is significantly inhibited in B cell-deficient mice. Absence of 
B cells is associated with increased infiltration of Th1 cells, CD8 T cells, and NK cells in the tumor. 
Conversely, adoptive transfer of B cells into immunodeficient mice results in increased tumor growth. 
 
The role of B cells in neoplasia has also been evaluated in genetically modified mouse models. In 
K14-HPV16-induced epithelial carcinogenesis, tumor progression is decreased in immunodeficient 
mice with no mature B and T cells (4). Adoptive transfer of B cells into these immunodeficient mice 
results in increased malignancy. Interestingly, depleting B cells with anti-CD20 monoclonal antibody 
(mAb) alone does not inhibit tumor progression, but improves response in combination with 
chemotherapy (5). One suggested mechanism for TIL-B enhancement of tumor progression is through 
a subset of B cells that are suppressive, thereby inhibiting the anti-tumor immune responses (6). 
Similarly, in a transgenic metastatic, castration resistant prostate cancer model (7), progression of the 
disease is associated with immune infiltrates including B cells, which are recruited to the tumor by the 
chemokine CXCL13. Tumors are refractory to the chemotherapeutic agent oxaliplatin unless mice are 
depleted of B cells. B cells inhibited anti-tumor responses of CD8 T cells through regulating IL-10 
and PD-L1 in that model. 
 
To date, the role of TIL-Bs in PDAC has not been investigated. By employing different approaches in 
various preclinical models, the three reports in the current issue of Cancer Discovery provide 
compelling evidence for the involvement of TIL-Bs in supporting both early and more advanced 
stages of pancreatic tumorigenesis. This occurs via multiple mechanisms, including suppression of 
other immune cells (e.g., CD8 T cells and macrophages) in the tumor microenvironment and 
promoting pancreatic cancer cell proliferation. Inhibition of B cell infiltration into the tumor by 
blocking chemokine CXCL13, inhibition of B cell activity using Bruton’s tyrosine kinase (BTK) 
inhibitor, or simple depletion of B cells using a specific mAb all significantly reduced tumor 
progression. 
 
Pylayeva-Gupta and colleagues (8) used primary human pancreatic intraepithelial neoplasia (PanIN) 
and the LSL-KrasG12D x p48Cre (KC) mouse model of PDAC to demonstrate significant presence of B 
cells in the proximity of PanIN lesions. Using the KC model, they further demonstrated that 
CD1dhiCD5+ B cell subsets contribute to pancreatic pathogenesis through a paracrine mechanism (IL-
35; heterodimer of subunits p35 and EB13) that promotes proliferation of the transformed epithelium. 
Importantly, the B cell chemoattaractant CXCL13, secreted by the fibroinflammatory stroma in 
human and mouse PanIN lesions, was shown to be responsible for the influx of B cells into the tumor. 
Treatment of tumor-bearing mice with a CXCL13 blocking mAb reduced B cell infiltration in KC 
mice and mice orthotopically implanted with KrasG12D-PDEC cells. 
 
On the other hand, Lee and co-workers (9) used primary human pancreatic tumors and the KC mouse 
model (crossed to HIF1αfl/fl) to demonstrate that HIF-1α is highly expressed during the preinvasive 
stage of PDAC and deletion of HIF-1α accelerates PDAC development in KC mice. Unexpectedly, 
elimination of HIF-1α resulted in an increased secretion of B cell chemoattractants (CXCL13, CCL19, 
CCL20, CCL21, and CXCL12), which, in turn, promoted intratumoral accumulation of the 
CD19+CD43+IgMhiCD5+ subset of B1b cells during early pancreatic neoplasia. In line with these 
observations, depletion of B cells reduced progression of PanIN and development of invasive 
carcinoma in tumor-bearing mice. As above, immunohistochemical analysis of primary human 
pancreatic tissues also revealed a significant presence of intrapancreatic B cells, supporting the 
involvement of human B cells in pancreatic tumorigenesis.  
 
Lastly, Gunderson et al. (10) used primary human pancreatic tumors, public databases, and two 
syngeneic murine PDAC cell lines – derived from primary pancreatic carcinomas of transgenic 
KrasG12D x PdxCre mice harboring p16Ink4α or p53 – to demonstrate that BTK regulates B cell and 
macrophage-mediated T cell suppression in PDAC development. Both human and murine PDACs 
were shown to exhibit high BTK activation in tumor-resident B cells and macrophages. BTK 
inhibition with the FDA-approved inhibitor ibritinib reduced PDAC growth and abated 
immunosuppression in vivo by reprogramming macrophages towards an M1 phenotype which 
promoted CD8 T cell cytotoxicity.  
 
One caveat to the three studies is that, in a number of the pre-clinical models used, the contribution of 
infiltrating B cells to pancreatic tumorigenesis was monitored in orthotopically engrafted tumors. As 
this involves a major surgery in the recipient mice, it could in turn create a local inflammatory 
environment that promotes a higher than normal infiltration of B cells into the tumor site and hence 
the data obtained from these models should be interpreted with caution. Additionally, there are 
conflicting reports on the role of TIL-Bs in other tumor types demonstrating the need for further study 
(2). Nevertheless, findings from the three studies provide compelling evidence for the involvement of 
tumor-infiltrating B cells in the initiation and progression of PDAC. 
 
In addition to advancing the overall field of immuno-oncology, findings from the three studies point 
to novel approaches for treating PDAC. Increasing the success rate for treating PDAC is likely to 
require combination therapies that target both tumor cells and immune cells as well as earlier 
detection and intervention. Currently, T cell-centric immunotherapies are being tested in late-stage 
PDAC. One new therapeutic strategy for PDAC would include targeted B cell suppression, such as 
BTK inhibition or depletion, as part of a combination therapy. Similarly, neutralizing IL-35 and/or 
CXCL13 in combination therapies may increase therapeutic efficacy. Moreover, the level of B cells, 
IL-35, and CXCL13 in the pancreas and/or PDAC may serve as biomarkers for early diagnosis, 
especially in higher risk individuals who are pre-disposed to developing PDAC due to family history 
(e.g., BRCA mutation and diabetes) or tobacco usage, helping clinicians develop earlier interventions.  
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Figure 1. Contribution of TIL-Bs to pancreatic tumorigenesis. B cells infiltrate pancreatic tissues 
in response to the release of local chemokines such as CXCL13. The TIL-Bs in turn secrete IL-35 that 
stimulate tumor cell proliferation (Pylayeva-Gupta et al., 2016). On the other hand, pancreas-specific 
HIF1α deletion accelerates pancreatic neoplasia and results in increased secretion of B cell 
chemokines and B cell infiltration into the pancreas (Lee et al., 2016). Furthermore, PDAC growth 
depends on crosstalk between B cells and FcγR+ TAMs, resulting in M2 programming via BTK 
activation in a PI3Kγ-dependent manner (Gunderson et al., 2016). Inhibiting B cell infiltration, 
depleting B cells or upregulation of HIF1α in pancreatic tumor microenvironment stimulates immune 
activation and inhibits tumorigenesis.  
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